Documentos relacionados

1. Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.
2. Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study.
3. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
4. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
5. Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease.
6. Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination.
7. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
8. Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance-associated substitution test.
9. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.
10. Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens.